Dr. Kamran Qureshi, MD

Dr. Qureshi practices at SSM Health Saint Louis University Hospital in Saint Louis, Missouri, part of SSM Health Care.

Dr. Qureshi's NPI, 1417119926, was assigned on June 26, 2008. Dr. Qureshi holds Missouri license 2018020853.

Dr. Qureshi's primary practice is SSM Health Saint Louis University Hospital, at 1201 S Grand Blvd, Saint Louis, MO 63104 in St. Louis City. The practice phone is (314) 257-8000.

Dr. Qureshi's primary practice is SSM Health Saint Louis University Hospital in Saint Louis, Missouri, part of SSM Health Care. Dr. Qureshi is also affiliated with SSM Health St. Mary's Hospital - St. Louis. The medical group on file is SLUCare Physician Group. Dmand AI also links Dr. Qureshi to 3 more hospitals, 3 medical groups, 2 group practices and clinics and 1 behavioral health center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Qureshi practices, 8 sites in all. Vendor and product names are available with a free account.

Transplant hepatology is Dr. Qureshi's primary specialty in the NPI Registry, under taxonomy code 207RT0003X. Dmand AI has Dr. Qureshi's licenses on file in 2 states: Missouri and Illinois.

CMS data shows 321 Medicare services from Dr. Qureshi across 10 procedure codes in 2024, for 215 Medicare patients. Medicare paid $26,590 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 215 Medicare patients who saw Dr. Qureshi in 2024. The largest group is 65 to 74, with 111 patients. 75% of them have high blood pressure, and 66% have high cholesterol. 28% are also on Medicaid. Their average risk score is 3.05, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Qureshi's median patient age at 64, with 52% women.

In 2024, Dr. Qureshi wrote 1,078 Medicare Part D claims for 211 patients. 75% of them were for generic drugs. CMS names the drug for 870 of them, across 27 drugs with 11 or more claims each, at $553,161 in total drug cost. In 2023, CMS named 840 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Qureshi for performance year 2024, reported as part of a group. Dr. Qureshi accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Colonoscopy: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 29 papers to Dr. Qureshi, published from 2014 to 2025. 2025 was the busiest year, with 6. The most frequent topics are Liver Transplantation, Hepatitis C, Chronic and Liver Cirrhosis. Dr. Qureshi has published most often in Aliment Pharmacol Ther. Dr. Qureshi's most frequent co-authors are Hicham Khallafi, MD, Abdullah M. S. Al-Osaimi, MD and Gregory Everson, MD.

Dmand AI links Dr. Qureshi to 2 clinical trials. 1 is still active or recruiting. Conditions studied include alpha 1-Antitrypsin Deficiency and Subcutaneous Emphysema. Open Payments lists research payments to Dr. Qureshi that name 1 trial.

CMS Open Payments shows 259 general payments to Dr. Qureshi from 27 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 64% of the total. Gilead Sciences, Inc. paid the most, $92,143. It also lists 3 research payments totaling $3,650 in 2025, naming 1 clinical trial.